[Etanercept in Juvenile Psoriasis]

Overview

Journal Hautarzt

Specialty Dermatology

Date 2012 May 11

PMID 22573316

Citations 2

Authors

F C Beikert

M Augustin

M A Radtke

Affiliations

Soon will be listed here.

Abstract

Background: With a prevalence of 0.71%, psoriasis represents one of the most frequent dermatoses in childhood.

Patients And Methods: Eight children with severe psoriasis who failed to respond to other therapy received a weight- adapted treatment with etanercept (0.8 mg/kg body) administered subcutaneously once weekly after latent tuberculosis had been excluded. Follow-up visits were at week 4 and 12, subsequently every 12 weeks.

Results: Mean age at the start of treatment was 11.8 (range 7-16), six patients were boys. Within three months, six patients reached Psoriasis Area and Severity Index (PASI) reduction of 75%. Two patients stopped use at week 12 because of ineffectiveness. Apart from local side reactions and minor infections, no adverse events were observed.

Conclusion: In our case series, etanercept proved to be an efficient drug in juvenile psoriasis without serious adverse events. However, patient registries and further randomized, double-blinded control studies are crucial to evaluate long-term efficacy and safety of etanercept.

Citing Articles

Systemic Treatment of Pediatric Psoriasis: A Review.

Napolitano M, Megna M, Balato A, Ayala F, Lembo S, Villani A Dermatol Ther (Heidelb). 2016; 6(2):125-42.

PMID: 27085539 PMC: 4906111. DOI: 10.1007/s13555-016-0117-6.

Anti-TNF agents for paediatric psoriasis.

Sanclemente G, Murphy R, Contreras J, Garcia H, Bonfill Cosp X Cochrane Database Syst Rev. 2015; (11):CD010017.

PMID: 26598969 PMC: 6493213. DOI: 10.1002/14651858.CD010017.pub2.

References

Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J . Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology. 2007; 132(3):863-73. DOI: 10.1053/j.gastro.2006.12.003. View

Raychaudhuri S, Gross J . A comparative study of pediatric onset psoriasis with adult onset psoriasis. Pediatr Dermatol. 2000; 17(3):174-8. DOI: 10.1046/j.1525-1470.2000.01746.x. View

Muhlbauer B, Janhsen K, Pichler J, Schoettler P . Off-label use of prescription drugs in childhood and adolescence: an analysis of prescription patterns in Germany. Dtsch Arztebl Int. 2009; 106(3):25-31. PMC: 2695292. DOI: 10.3238/arztebl.2009.0025. View

Leman J, Burden D . Psoriasis in children: a guide to its diagnosis and management. Paediatr Drugs. 2001; 3(9):673-80. DOI: 10.2165/00128072-200103090-00005. View

Papoutsaki M, Costanzo A, Mazzotta A, Gramiccia T, Soda R, Chimenti S . Etanercept for the treatment of severe childhood psoriasis. Br J Dermatol. 2006; 154(1):181-3. DOI: 10.1111/j.1365-2133.2005.06982.x. View

Lamot L, Bukovac L, Vidovic M, Frleta M, Harjacek M . The 'head-to-head' comparison of etanercept and infliximab in treating children with juvenile idiopathic arthritis. Clin Exp Rheumatol. 2011; 29(1):131-9. View

Viola F, Civitelli F, Di Nardo G, Barbato M, Borrelli O, Oliva S . Efficacy of adalimumab in moderate-to-severe pediatric Crohn's disease. Am J Gastroenterol. 2009; 104(10):2566-71. DOI: 10.1038/ajg.2009.372. View

Benoit S, Hamm H . Childhood psoriasis. Clin Dermatol. 2007; 25(6):555-62. DOI: 10.1016/j.clindermatol.2007.08.009. View

Hawrot A, Metry D, Theos A, Levy M . Etanercept for psoriasis in the pediatric population: experience in nine patients. Pediatr Dermatol. 2006; 23(1):67-71. DOI: 10.1111/j.1525-1470.2006.00174.x. View

10.

Augustin M, Glaeske G, Radtke M, Christophers E, Reich K, Schafer I . Epidemiology and comorbidity of psoriasis in children. Br J Dermatol. 2009; 162(3):633-6. DOI: 10.1111/j.1365-2133.2009.09593.x. View

11.

Sticherling M, Augustin M, Boehncke W, Christophers E, Domm S, Gollnick H . Therapy of psoriasis in childhood and adolescence - a German expert consensus. J Dtsch Dermatol Ges. 2011; 9(10):815-23. DOI: 10.1111/j.1610-0387.2011.07668.x. View

12.

Stahle M, Atakan N, Boehncke W, Chimenti S, Dauden E, Giannetti A . Juvenile psoriasis and its clinical management: a European expert group consensus. J Dtsch Dermatol Ges. 2010; 8(10):812-8. DOI: 10.1111/j.1610-0387.2010.07507.x. View

13.

Langley R, Paller A, Hebert A, Creamer K, Weng H, Jahreis A . Patient-reported outcomes in pediatric patients with psoriasis undergoing etanercept treatment: 12-week results from a phase III randomized controlled trial. J Am Acad Dermatol. 2010; 64(1):64-70. DOI: 10.1016/j.jaad.2010.02.060. View

14.

de Jager M, de Jong E, van de Kerkhof P, Seyger M . Efficacy and safety of treatments for childhood psoriasis: a systematic literature review. J Am Acad Dermatol. 2009; 62(6):1013-30. DOI: 10.1016/j.jaad.2009.06.048. View

15.

Rosh J, Lerer T, Markowitz J, Goli S, Mamula P, Noe J . Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease. Am J Gastroenterol. 2009; 104(12):3042-9. DOI: 10.1038/ajg.2009.493. View

16.

Hyams J, Lerer T, Griffiths A, Pfefferkorn M, Stephens M, Evans J . Outcome following infliximab therapy in children with ulcerative colitis. Am J Gastroenterol. 2010; 105(6):1430-6. DOI: 10.1038/ajg.2009.759. View

17.

Paller A, Siegfried E, Langley R, Gottlieb A, Pariser D, Landells I . Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med. 2008; 358(3):241-51. DOI: 10.1056/NEJMoa066886. View

18.

Kress D . Etanercept therapy improves symptoms and allows tapering of other medications in children and adolescents with moderate to severe psoriasis. J Am Acad Dermatol. 2006; 54(3 Suppl 2):S126-8. DOI: 10.1016/j.jaad.2005.10.056. View

19.

Lovell D, Giannini E, Reiff A, Cawkwell G, Silverman E, Nocton J . Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med. 2000; 342(11):763-9. DOI: 10.1056/NEJM200003163421103. View